Our Offerings
By Industry By Function
About Us
Our Viewpoint
NEW
 Senior Management Experts Panel Global Consultants Press Releases Blog
Infographics Market Insights Case Studies Illustrations In The Press
Contact Us
The Business Research Company Logo
Reports Store
Top 50 Healthcare Market Reports
NEW
 Top 50 Non-Healthcare Market Reports
NEW
 Opportunities And Strategies Reports Aerospace And Defense Agriculture Chemicals Construction
Electrical And Electronics Financial Services Food And Beverages Healthcare Services Hospitality Information Technology Machinery Media
Medical Equipment Metal And Mineral Mining Oil And Gas Paper, Plastics, Rubber, Wood And Textile Pharmaceuticals Professional Services Recreation
Retail And Wholesale Services Social Services Transport Transport Services Utilities Veterinary Healthcare Filter Reports by Trends
NEW
Market Intelligence Platform
About GMM Global Forecast
NEW
 Mega Trends Analysis
Consultancies Corporate Planning & Strategy Academic Financial Services Legal Services
Pricing Methodology Sources FAQ Press Coverage
Customized Research
Find Customers Optimise Your Marketing Mix Evaluate Competitors Identify Market Opportunities Develop Products And Services
Distributor And Partner Research Plan Finances Streamline Your Operations Devise Market Entry Strategy Explore Custom Research Packages
NEW
Continuous Research
Desk Research Research Reports Senior Executive Interviews Consumer Research Market Sizing And Forecasts
Company Information Analytics And Data Visualization Research Automation Web Crawling And Spidering AI-Empowered Research Services
Request Proposal
Glucagon-like Peptide 1 Global Market Report 2025
Download Free Sample Buy Now
Global Glucagon-like Peptide 1 Market Report 2025

Report Price : $4490.00

Pages :

Format : PDF

Published : December 2025

Delivery Time : 2-3 Business Days

Purchase This Report Download Sample PDF
Purchase This Report

Glucagon-like Peptide 1 Global Market Report 2025

By Product (Trulicity, Ozempic, Victoza, Rybelsus, Other Types), By Route of Administration (Oral, Parenteral, Other Routes), By End-Users (Hospitals, Specialty Clinics, Other End Users) – Impact of Tariff and Trade War on Market Size, Growth, Trends, and Forecast 2025–2034

Note that the outlook for this market is being affected by rapid changes in trade relations and tariffs globally. The report will be updated prior to delivery to reflect the latest status, including revised forecasts and quantified impact analysis. The report’s Recommendations and Conclusions sections will be updated to give strategies for entities dealing with the fast-moving international environment.

Glucagon-like Peptide 1 Market Overview

• Glucagon-like Peptide 1 market size has reached to $20.88 billion in 2024

• Expected to grow to $30.5 billion in 2029 at a compound annual growth rate (CAGR) of 8.4%

• Growth Driver: Escalating Diabetes Prevalence Drives The Global Glucagon-Like Peptide 1 Market

• Market Trend: Novo Nordisk Introduces Wegovy Therapy For Weight Management

• North America was the largest region in 2024 and is the fastest growing region.

What Is Covered Under Glucagon-like Peptide 1 Market?

Glucagon-like peptide 1 refers to a type of amino acid hormone of peptide that is produced in the L-cells of the intestinal epithelial endocrine. Glucagon-like peptide 1 is used to treat diseases and conditions such as diabetes and obesity respectively.

The main glucagon-like peptide 1 product types are trulicity, ozempic, victoza, rybelsus, and others. Trulicity refers to a prescription medicine that is injectable and is used to improve blood sugar. The various routes of administration are oral, parenteral, and others used in hospitals, specialty clinics, and others.

Glucagon-like Peptide 1 Market Size and growth rate 2025 to 2029: Graph

What Is The Glucagon-like Peptide 1 Market Size 2025 And Growth Rate?

The glucagon-like peptide 1 market size has grown strongly in recent years. It will grow from$20.88 billion in 2024 to $22.06 billion in 2025 at a compound annual growth rate (CAGR) of 5.7%. The growth in the historic period can be attributed to rising prevalence of diabetes, focus on improved diabetes management, patient preference for injectable therapies, clinical efficacy and safety profiles, advancements in diabetes research

What Is The Glucagon-like Peptide 1 Market Growth Forecast?

The glucagon-like peptide 1 market size is expected to see strong growth in the next few years. It will grow to $30.5 billion in 2029 at a compound annual growth rate (CAGR) of 8.4%. The growth in the forecast period can be attributed to emergence of oral glp-1 therapies, focus on personalized medicine, integration in diabetes treatment algorithms, patient-centric approaches in healthcare. Major trends in the forecast period include market expansion in emerging economies, regulatory approvals for new formulations, focus on personalized medicine, patient education and awareness programs, competitive landscape dynamics.

The forecast of 8.4% growth over the next five years reflects a modest reduction of 0.3% from the previous estimate for this market.This reduction is primarily due to the impact of tariffs between the US and other countries. This is likely to directly affect the US by raising diabetes treatment costs, as tariffs on peptide APIs from Denmark and Switzerland increase pharmaceutical production expenses.The effect will also be felt more widely due to reciprocal tariffs and the negative effect on the global economy and trade due to increased trade tensions and restrictions.

Customer representative image Book your 30 minutes free consultation with our research experts
Contact Us

What’s The Trade War Impact On Chemicals Industry?

The intensifying U.S. tariffs and escalating trade tensions in spring 2025 are expected to have a significant impact on the chemicals sector, which is bearing a disproportionate burden, particularly from tariffs on petrochemicals and intermediates, where affordable domestic substitutes are often unavailable. Producers of specialty chemicals, heavily dependent on Chinese raw materials, are experiencing production disruptions. At the same time, fertilizer manufacturers are seeing profit margins eroded due to tariffs on phosphate imports. In response, companies are ramping up R&D into bio-based alternatives, forming procurement alliances to consolidate buying power, and shifting production to tariff-neutral nations such as Saudi Arabia.

How Is The Glucagon-like Peptide 1 Market Segmented?

1) By Product: Trulicity, Ozempic, Victoza, Rybelsus, Other Types

2) By Route of Administration: Oral, Parenteral, Other Routes

3) By End-Users: Hospitals, Specialty Clinics, Other End Users

Subsegments:

1) By Trulicity: Injection (pre-filled pen), Dosage forms (0.75 mg, 1.5 mg, etc.)

2) By Ozempic: Injection (pre-filled pen), Dosage forms (0.5 mg, 1 mg, etc.)

3) By Victoza: Injection (pre-filled pen), Dosage forms (1.2 mg, 1.8 mg, etc.)

4) By Rybelsus: Oral tablet (3 mg, 7 mg, 14 mg)

5) By Other Types: Experimental formulations, Combination products with other medications, Alternative delivery systems

What Is Driving The Glucagon-like Peptide 1 Market? Escalating Diabetes Prevalence Drives The Global Glucagon-Like Peptide 1 Market

The rising prevalence of diabetes is expected to propel the global glucagon-like peptide 1 market going forward. Diabetes is a condition in which the blood sugar, or blood glucose, is too high. Glucagon-like peptide 1 is a medication used to treat conditions such as type 2 diabetes that may lead to weight loss and improved blood sugar. For instance, in January 2022, according to the National Library of Medicine, a US-based center of biomedical informatics and computational biology, it was estimated that global diabetes prevalence in 20-79-year-olds in 2021 was 10.5% (536.6 million people), and it is expected to increase to 12.2% (783.2 million) in 2045. Therefore, the rising prevalence of diabetes will drive glucagon-like peptide 1.

What Is Driving The Glucagon-like Peptide 1 Market? Growing Health Awareness Fuels Demand For Glucagon-Like Peptide 1 (GLP-1) Market

Increasing emphasis on personalized medicine is expected to propel the growth of the glucagon-like peptide 1 (GLP-1) market going forward. Personalized medicine refers to a type of medication that prevents, detects, or treats disease using knowledge about a person's genes or proteins. Personalized medicine allows for the tailoring of GLP-1 formulations and dosages based on individual patient needs and preferences. For instance, in 2022, according to the Personalized Medicine Coalition, a US-based professional membership organization, in 2022, the US Food and Drug Administration (FDA) approved 12 personalized medicines, which accounted for approximately 34% of all newly approved therapeutic molecular entities. Therefore, the increasing emphasis on personalized medicine is driving the growth of the glucagon-like peptide 1 (GLP-1) market.

Who Are The Major Players In The Global Glucagon-like Peptide 1 Market?

Major companies operating in the glucagon-like peptide 1 market include Novo Nordisk AS, Sanofi SA, Eli Lilly and Co, AstraZeneca plc, Pfizer Inc, Boehringer Ingelheim International GmbH, F Hoffmann-La Roche Ltd, Bristol-Myers Squibb Company, Baxter, Hikma Pharmaceuticals plc, Zealand Pharma A/S, Intarcia Therapeutics Inc., GlaxoSmithKline plc, Jiangsu Hansoh Pharmaceutical Group Co Ltd, Shanghai Benemae Pharmaceutical Corporation, Adocia, Biocon, Hanmi Pharmaceutical Co Ltd, Ligand Pharmaceuticals Incorporated, Advinus Therapeutics Ltd, Mitsubishi Tanabe Pharma Corporation, Daiichi Sankyo Company Limited, Sun Pharmaceutical Industries Ltd, Union Chimique Belge, Amylin Pharmaceuticals LLC, Academic Pharmaceuticals Inc, ConjuChem Biotechnologies, MannKind Corporation:, Provention Bio Inc, Regeneron Pharmaceuticals

What Are The Key Trends Of The Global Glucagon-like Peptide 1 Market? Novo Nordisk Introduces Wegovy Therapy For Weight Management

Technological innovations are a key trend gaining popularity in the global glucagon-like peptide 1 market. Major companies operating in the glucagon-like peptide 1 market are launching new and innovative technologies to sustain their position in the market. For instance, in March 2024, Novo Nordisk A/S, a Denmark-based pharmaceutical company, launched Wegovy, the first and only once-weekly glucagon-like peptide 1 therapy for weight management. Wegovy completed the STEP Phase 3a clinical trial program and demonstrated a safe and well-tolerated profile across the program. This product is used by people who struggle with obesity to achieve and maintain weight loss.

What Are The Key Trends Of The Global Glucagon-like Peptide 1 Market? Innovation In Glucagon-Like Peptide 1 Market By Novo Nordisk India

Major companies operating in the Glucagon-like Peptide 1 market are focusing on product innovations such as oral semaglutide to sustain their position in the market. Oral semaglutide refers to a medication for diabetes management that comes in pill form and is taken by mouth. For instance, in January 2022, Novo Nordisk India, an India-based healthcare company that involves clinical trials, manufacturing, and the introduction of new drugs, launched oral semaglutide, a groundbreaking peptide-in-a-pill formulation. This innovation transforms diabetes treatment, offering patients an oral alternative to injections. This enhancer serves a dual purpose by safeguarding semaglutide from degradation in the stomach, a common challenge for peptides, and by enhancing its absorption.

Need data on a specific region in this market?
Request Regional Data

Glucagon-like Peptide 1 Market Merger And Acquisition: Novo Holdings’ Strategic Acquisition Of Catalent Inc.

In March 2024, Novo Holdings A/S, a Denmark-based investment company acquired Catalent Inc for $16.5 billion. With this acquisition, Novo Holdings aims to strengthen its footprint in the high-growth GLP-1 market by leveraging Catalent’s established infrastructure in fill-finish manufacturing, ensuring increased capacity to meet the rising demand for diabetes and weight-loss treatments. Catalent Inc is US-based biotechnology company specializes in advanced delivery technologies and development solutions for pharmaceuticals.

Regional Analysis For The Global Glucagon-like Peptide 1 Market

North America was the largest region in the glucagon-like peptide 1 market in 2024. The regions covered in this market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa

The countries covered in this market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain

What Defines the Glucagon-like Peptide 1 Market?

The glucagon-like peptide 1 market consists of sales of dulaglutide, albiglutide, semaglutide, and tirzepatide. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

How is Market Value Defined and Measured?

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

What is the Market Assessment and Strategic Outlook for the Glucagon-like Peptide 1 Industry?

The glucagon-like peptide 1 market research report is one of a series of new reports from The Business Research Company that provides market statistics, including industry global market size, regional shares, competitors with the market share, detailed market segments, market trends and opportunities, and any further data you may need to thrive in the glucagon-like peptide 1 industry. The market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future state of the industry.

Glucagon-like Peptide 1 Market Report Forecast Analysis

Report AttributeDetails
Market Size Value In 2025 $22.06 billion
Revenue Forecast In 2034 $30.5 billion
Growth Rate CAGR of 8.4% from 2025 to 2034
Base Year For Estimation 2024
Actual Estimates/Historical Data 2019-2024
Forecast Period 2025 - 2029 - 2034
Market Representation Revenue in USD Billion and CAGR from 2025 to 2034
Segments Covered 1) By Product: Trulicity, Ozempic, Victoza, Rybelsus, Other Types
2) By Route of Administration: Oral, Parenteral, Other Routes
3) By End-Users: Hospitals, Specialty Clinics, Other End Users Subsegments: 1) By Trulicity: Injection (pre-filled pen), Dosage forms (0.75 mg, 1.5 mg, etc.)
2) By Ozempic: Injection (pre-filled pen), Dosage forms (0.5 mg, 1 mg, etc.)
3) By Victoza: Injection (pre-filled pen), Dosage forms (1.2 mg, 1.8 mg, etc.)
4) By Rybelsus: Oral tablet (3 mg, 7 mg, 14 mg)
5) By Other Types: Experimental formulations, Combination products with other medications, Alternative delivery systems
Regional Scope Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa
Country Scope The countries covered in the report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain. Additional countries that can be covered in the report are Bangladesh, Thailand, Vietnam, Malaysia, Singapore, Philippines, Hong Kong, New Zealand, Mexico, Chile, Argentina, Colombia, Peru, Austria, Belgium, Denmark, Finland, Ireland, Netherlands, Norway, Portugal, Sweden, Switzerland, Czech Republic, Poland, Romania, Ukraine, Saudi Arabia, Israel, Iran, Turkey, UAE, Egypt, Nigeria, South Africa.
Key Companies Profiled Novo Nordisk AS, Sanofi SA, Eli Lilly and Co, AstraZeneca plc, Pfizer Inc, Boehringer Ingelheim International GmbH, F Hoffmann-La Roche Ltd, Bristol-Myers Squibb Company, Baxter, Hikma Pharmaceuticals plc, Zealand Pharma A/S, Intarcia Therapeutics Inc., GlaxoSmithKline plc, Jiangsu Hansoh Pharmaceutical Group Co Ltd, Shanghai Benemae Pharmaceutical Corporation, Adocia, Biocon, Hanmi Pharmaceutical Co Ltd, Ligand Pharmaceuticals Incorporated, Advinus Therapeutics Ltd, Mitsubishi Tanabe Pharma Corporation, Daiichi Sankyo Company Limited, Sun Pharmaceutical Industries Ltd, Union Chimique Belge, Amylin Pharmaceuticals LLC, Academic Pharmaceuticals Inc, ConjuChem Biotechnologies, MannKind Corporation:, Provention Bio Inc, Regeneron Pharmaceuticals
Customization ScopeRequest for Sample
Pricing And Purchase OptionsExplore Purchase Options

Table Of Contents

1. Executive Summary

2. Glucagon-like Peptide 1 Market Characteristics

3. Glucagon-like Peptide 1 Market Trends And Strategies

4. Glucagon-like Peptide 1 Market - Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics, Trade Wars and Tariffs, And Covid And Recovery On The Market

4.1. Supply Chain Impact from Tariff War & Trade Protectionism

5. Global Glucagon-like Peptide 1 Growth Analysis And Strategic Analysis Framework

5.1. Global Glucagon-like Peptide 1 PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)

5.2. Analysis Of End Use Industries

5.3. Global Glucagon-like Peptide 1 Market Growth Rate Analysis

5.4. Global Glucagon-like Peptide 1 Historic Market Size and Growth, 2019 - 2024, Value ($ Billion)

5.5. Global Glucagon-like Peptide 1 Forecast Market Size and Growth, 2024 - 2029, 2034F, Value ($ Billion)

5.6. Global Glucagon-like Peptide 1 Total Addressable Market (TAM)

6. Glucagon-like Peptide 1 Market Segmentation

6.1. Global Glucagon-like Peptide 1 Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Trulicity

Ozempic

Victoza

Rybelsus

Other Types

6.2. Global Glucagon-like Peptide 1 Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Oral

Parenteral

Other Routes

6.3. Global Glucagon-like Peptide 1 Market, Segmentation By End-Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Hospitals

Specialty Clinics

Other End Users

6.4. Global Glucagon-like Peptide 1 Market, Sub-Segmentation Of Trulicity, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Injection (pre-filled pen)

Dosage forms (0.75 mg, 1.5 mg, etc.)

6.5. Global Glucagon-like Peptide 1 Market, Sub-Segmentation Of Ozempic, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Injection (pre-filled pen)

Dosage forms (0.5 mg, 1 mg, etc.)

6.6. Global Glucagon-like Peptide 1 Market, Sub-Segmentation Of Victoza, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Injection (pre-filled pen)

Dosage forms (1.2 mg, 1.8 mg, etc.)

6.7. Global Glucagon-like Peptide 1 Market, Sub-Segmentation Of Rybelsus, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Oral tablet (3 mg, 7 mg, 14 mg)

6.8. Global Glucagon-like Peptide 1 Market, Sub-Segmentation Of Other Types, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Experimental formulations

Combination products with other medications

Alternative delivery systems

7. Glucagon-like Peptide 1 Market Regional And Country Analysis

7.1. Global Glucagon-like Peptide 1 Market, Split By Region, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

7.2. Global Glucagon-like Peptide 1 Market, Split By Country, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

8. Asia-Pacific Glucagon-like Peptide 1 Market

8.1. Asia-Pacific Glucagon-like Peptide 1 Market Overview

Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies

8.2. Asia-Pacific Glucagon-like Peptide 1 Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

8.3. Asia-Pacific Glucagon-like Peptide 1 Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

8.4. Asia-Pacific Glucagon-like Peptide 1 Market, Segmentation By End-Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

9. China Glucagon-like Peptide 1 Market

9.1. China Glucagon-like Peptide 1 Market Overview

9.2. China Glucagon-like Peptide 1 Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion

9.3. China Glucagon-like Peptide 1 Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion

9.4. China Glucagon-like Peptide 1 Market, Segmentation By End-Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion

10. India Glucagon-like Peptide 1 Market

10.1. India Glucagon-like Peptide 1 Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

10.2. India Glucagon-like Peptide 1 Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

10.3. India Glucagon-like Peptide 1 Market, Segmentation By End-Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

11. Japan Glucagon-like Peptide 1 Market

11.1. Japan Glucagon-like Peptide 1 Market Overview

11.2. Japan Glucagon-like Peptide 1 Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

11.3. Japan Glucagon-like Peptide 1 Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

11.4. Japan Glucagon-like Peptide 1 Market, Segmentation By End-Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

12. Australia Glucagon-like Peptide 1 Market

12.1. Australia Glucagon-like Peptide 1 Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

12.2. Australia Glucagon-like Peptide 1 Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

12.3. Australia Glucagon-like Peptide 1 Market, Segmentation By End-Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

13. Indonesia Glucagon-like Peptide 1 Market

13.1. Indonesia Glucagon-like Peptide 1 Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

13.2. Indonesia Glucagon-like Peptide 1 Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

13.3. Indonesia Glucagon-like Peptide 1 Market, Segmentation By End-Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

14. South Korea Glucagon-like Peptide 1 Market

14.1. South Korea Glucagon-like Peptide 1 Market Overview

14.2. South Korea Glucagon-like Peptide 1 Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

14.3. South Korea Glucagon-like Peptide 1 Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

14.4. South Korea Glucagon-like Peptide 1 Market, Segmentation By End-Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

15. Western Europe Glucagon-like Peptide 1 Market

15.1. Western Europe Glucagon-like Peptide 1 Market Overview

15.2. Western Europe Glucagon-like Peptide 1 Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

15.3. Western Europe Glucagon-like Peptide 1 Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

15.4. Western Europe Glucagon-like Peptide 1 Market, Segmentation By End-Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

16. UK Glucagon-like Peptide 1 Market

16.1. UK Glucagon-like Peptide 1 Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

16.2. UK Glucagon-like Peptide 1 Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

16.3. UK Glucagon-like Peptide 1 Market, Segmentation By End-Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

17. Germany Glucagon-like Peptide 1 Market

17.1. Germany Glucagon-like Peptide 1 Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

17.2. Germany Glucagon-like Peptide 1 Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

17.3. Germany Glucagon-like Peptide 1 Market, Segmentation By End-Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

18. France Glucagon-like Peptide 1 Market

18.1. France Glucagon-like Peptide 1 Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

18.2. France Glucagon-like Peptide 1 Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

18.3. France Glucagon-like Peptide 1 Market, Segmentation By End-Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

19. Italy Glucagon-like Peptide 1 Market

19.1. Italy Glucagon-like Peptide 1 Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

19.2. Italy Glucagon-like Peptide 1 Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

19.3. Italy Glucagon-like Peptide 1 Market, Segmentation By End-Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

20. Spain Glucagon-like Peptide 1 Market

20.1. Spain Glucagon-like Peptide 1 Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

20.2. Spain Glucagon-like Peptide 1 Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

20.3. Spain Glucagon-like Peptide 1 Market, Segmentation By End-Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

21. Eastern Europe Glucagon-like Peptide 1 Market

21.1. Eastern Europe Glucagon-like Peptide 1 Market Overview

21.2. Eastern Europe Glucagon-like Peptide 1 Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

21.3. Eastern Europe Glucagon-like Peptide 1 Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

21.4. Eastern Europe Glucagon-like Peptide 1 Market, Segmentation By End-Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

22. Russia Glucagon-like Peptide 1 Market

22.1. Russia Glucagon-like Peptide 1 Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

22.2. Russia Glucagon-like Peptide 1 Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

22.3. Russia Glucagon-like Peptide 1 Market, Segmentation By End-Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

23. North America Glucagon-like Peptide 1 Market

23.1. North America Glucagon-like Peptide 1 Market Overview

23.2. North America Glucagon-like Peptide 1 Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

23.3. North America Glucagon-like Peptide 1 Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

23.4. North America Glucagon-like Peptide 1 Market, Segmentation By End-Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

24. USA Glucagon-like Peptide 1 Market

24.1. USA Glucagon-like Peptide 1 Market Overview

24.2. USA Glucagon-like Peptide 1 Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

24.3. USA Glucagon-like Peptide 1 Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

24.4. USA Glucagon-like Peptide 1 Market, Segmentation By End-Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

25. Canada Glucagon-like Peptide 1 Market

25.1. Canada Glucagon-like Peptide 1 Market Overview

25.2. Canada Glucagon-like Peptide 1 Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

25.3. Canada Glucagon-like Peptide 1 Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

25.4. Canada Glucagon-like Peptide 1 Market, Segmentation By End-Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

26. South America Glucagon-like Peptide 1 Market

26.1. South America Glucagon-like Peptide 1 Market Overview

26.2. South America Glucagon-like Peptide 1 Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

26.3. South America Glucagon-like Peptide 1 Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

26.4. South America Glucagon-like Peptide 1 Market, Segmentation By End-Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

27. Brazil Glucagon-like Peptide 1 Market

27.1. Brazil Glucagon-like Peptide 1 Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

27.2. Brazil Glucagon-like Peptide 1 Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

27.3. Brazil Glucagon-like Peptide 1 Market, Segmentation By End-Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

28. Middle East Glucagon-like Peptide 1 Market

28.1. Middle East Glucagon-like Peptide 1 Market Overview

28.2. Middle East Glucagon-like Peptide 1 Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

28.3. Middle East Glucagon-like Peptide 1 Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

28.4. Middle East Glucagon-like Peptide 1 Market, Segmentation By End-Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

29. Africa Glucagon-like Peptide 1 Market

29.1. Africa Glucagon-like Peptide 1 Market Overview

29.2. Africa Glucagon-like Peptide 1 Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

29.3. Africa Glucagon-like Peptide 1 Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

29.4. Africa Glucagon-like Peptide 1 Market, Segmentation By End-Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

30. Glucagon-like Peptide 1 Market Competitive Landscape And Company Profiles

30.1. Glucagon-like Peptide 1 Market Competitive Landscape

30.2. Glucagon-like Peptide 1 Market Company Profiles

30.2.1. Novo Nordisk AS Overview, Products and Services, Strategy and Financial Analysis

30.2.2. Sanofi SA Overview, Products and Services, Strategy and Financial Analysis

30.2.3. Eli Lilly and Co Overview, Products and Services, Strategy and Financial Analysis

30.2.4. AstraZeneca plc Overview, Products and Services, Strategy and Financial Analysis

30.2.5. Pfizer Inc Overview, Products and Services, Strategy and Financial Analysis

31. Glucagon-like Peptide 1 Market Other Major And Innovative Companies

31.1. Boehringer Ingelheim International GmbH

31.2. F Hoffmann-La Roche Ltd

31.3. Bristol-Myers Squibb Company

31.4. Baxter

31.5. Hikma Pharmaceuticals plc

31.6. Zealand Pharma A/S

31.7. Intarcia Therapeutics Inc.

31.8. GlaxoSmithKline plc

31.9. Jiangsu Hansoh Pharmaceutical Group Co Ltd

31.10. Shanghai Benemae Pharmaceutical Corporation

31.11. Adocia

31.12. Biocon

31.13. Hanmi Pharmaceutical Co Ltd

31.14. Ligand Pharmaceuticals Incorporated

31.15. Advinus Therapeutics Ltd

32. Global Glucagon-like Peptide 1 Market Competitive Benchmarking And Dashboard

33. Key Mergers And Acquisitions In The Glucagon-like Peptide 1 Market

34. Recent Developments In The Glucagon-like Peptide 1 Market

35. Glucagon-like Peptide 1 Market High Potential Countries, Segments and Strategies

35.1 Glucagon-like Peptide 1 Market In 2029 - Countries Offering Most New Opportunities

35.2 Glucagon-like Peptide 1 Market In 2029 - Segments Offering Most New Opportunities

35.3 Glucagon-like Peptide 1 Market In 2029 - Growth Strategies

35.3.1 Market Trend Based Strategies

35.3.2 Competitor Strategies

36. Appendix

36.1. Abbreviations

36.2. Currencies

36.3. Historic And Forecast Inflation Rates

36.4. Research Inquiries

36.5. The Business Research Company

36.6. Copyright And Disclaimer

List Of Tables

    Table 1: Global Historic Market Growth, 2019-2024, $ Billion
  • Table 2: Global Forecast Market Growth, 2024-2029F, 2034F, $ Billion
  • Table 3: Global Glucagon-like Peptide 1 Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 4: Global Glucagon-like Peptide 1 Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 5: Global Glucagon-like Peptide 1 Market, Segmentation By End-Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 6: Global Glucagon-like Peptide 1 Market, Sub-Segmentation Of Trulicity, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 7: Global Glucagon-like Peptide 1 Market, Sub-Segmentation Of Ozempic, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 8: Global Glucagon-like Peptide 1 Market, Sub-Segmentation Of Victoza, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 9: Global Glucagon-like Peptide 1 Market, Sub-Segmentation Of Rybelsus, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 10: Global Glucagon-like Peptide 1 Market, Sub-Segmentation Of Other Types, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 11: Global Glucagon-like Peptide 1 Market, Split By Region, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 12: Global Glucagon-like Peptide 1 Market, Split By Country, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 13: Asia-Pacific, Glucagon-like Peptide 1 Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 14: Asia-Pacific, Glucagon-like Peptide 1 Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 15: Asia-Pacific, Glucagon-like Peptide 1 Market, Segmentation By End-Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 16: China, Glucagon-like Peptide 1 Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 17: China, Glucagon-like Peptide 1 Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 18: China, Glucagon-like Peptide 1 Market, Segmentation By End-Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 19: India, Glucagon-like Peptide 1 Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 20: India, Glucagon-like Peptide 1 Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 21: India, Glucagon-like Peptide 1 Market, Segmentation By End-Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 22: Japan, Glucagon-like Peptide 1 Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 23: Japan, Glucagon-like Peptide 1 Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 24: Japan, Glucagon-like Peptide 1 Market, Segmentation By End-Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 25: Australia, Glucagon-like Peptide 1 Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 26: Australia, Glucagon-like Peptide 1 Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 27: Australia, Glucagon-like Peptide 1 Market, Segmentation By End-Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 28: Indonesia, Glucagon-like Peptide 1 Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 29: Indonesia, Glucagon-like Peptide 1 Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 30: Indonesia, Glucagon-like Peptide 1 Market, Segmentation By End-Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 31: South Korea, Glucagon-like Peptide 1 Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 32: South Korea, Glucagon-like Peptide 1 Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 33: South Korea, Glucagon-like Peptide 1 Market, Segmentation By End-Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 34: Western Europe, Glucagon-like Peptide 1 Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 35: Western Europe, Glucagon-like Peptide 1 Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 36: Western Europe, Glucagon-like Peptide 1 Market, Segmentation By End-Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 37: UK, Glucagon-like Peptide 1 Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 38: UK, Glucagon-like Peptide 1 Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 39: UK, Glucagon-like Peptide 1 Market, Segmentation By End-Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 40: Germany, Glucagon-like Peptide 1 Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 41: Germany, Glucagon-like Peptide 1 Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 42: Germany, Glucagon-like Peptide 1 Market, Segmentation By End-Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 43: France, Glucagon-like Peptide 1 Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 44: France, Glucagon-like Peptide 1 Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 45: France, Glucagon-like Peptide 1 Market, Segmentation By End-Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 46: Italy, Glucagon-like Peptide 1 Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 47: Italy, Glucagon-like Peptide 1 Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 48: Italy, Glucagon-like Peptide 1 Market, Segmentation By End-Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 49: Spain, Glucagon-like Peptide 1 Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 50: Spain, Glucagon-like Peptide 1 Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 51: Spain, Glucagon-like Peptide 1 Market, Segmentation By End-Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 52: Eastern Europe, Glucagon-like Peptide 1 Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 53: Eastern Europe, Glucagon-like Peptide 1 Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 54: Eastern Europe, Glucagon-like Peptide 1 Market, Segmentation By End-Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 55: Russia, Glucagon-like Peptide 1 Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 56: Russia, Glucagon-like Peptide 1 Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 57: Russia, Glucagon-like Peptide 1 Market, Segmentation By End-Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 58: North America, Glucagon-like Peptide 1 Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 59: North America, Glucagon-like Peptide 1 Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 60: North America, Glucagon-like Peptide 1 Market, Segmentation By End-Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 61: USA, Glucagon-like Peptide 1 Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 62: USA, Glucagon-like Peptide 1 Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 63: USA, Glucagon-like Peptide 1 Market, Segmentation By End-Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 64: Canada, Glucagon-like Peptide 1 Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 65: Canada, Glucagon-like Peptide 1 Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 66: Canada, Glucagon-like Peptide 1 Market, Segmentation By End-Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 67: South America, Glucagon-like Peptide 1 Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 68: South America, Glucagon-like Peptide 1 Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 69: South America, Glucagon-like Peptide 1 Market, Segmentation By End-Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 70: Brazil, Glucagon-like Peptide 1 Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 71: Brazil, Glucagon-like Peptide 1 Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 72: Brazil, Glucagon-like Peptide 1 Market, Segmentation By End-Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 73: Middle East, Glucagon-like Peptide 1 Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 74: Middle East, Glucagon-like Peptide 1 Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 75: Middle East, Glucagon-like Peptide 1 Market, Segmentation By End-Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 76: Africa, Glucagon-like Peptide 1 Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 77: Africa, Glucagon-like Peptide 1 Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 78: Africa, Glucagon-like Peptide 1 Market, Segmentation By End-Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 79: Novo Nordisk AS Financial Performance
  • Table 80: Sanofi SA Financial Performance
  • Table 81: Eli Lilly and Co Financial Performance
  • Table 82: AstraZeneca plc Financial Performance
  • Table 83: Pfizer Inc Financial Performance

List Of Figures

    Figure 1: Global Historic Market Growth, 2019-2024, $ Billion
  • Figure 2: Global Forecast Market Growth, 2024-2029F, 2034F, $ Billion
  • Figure 3: Global Glucagon-like Peptide 1 Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 4: Global Glucagon-like Peptide 1 Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 5: Global Glucagon-like Peptide 1 Market, Segmentation By End-Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 6: Global Glucagon-like Peptide 1 Market, Sub-Segmentation Of Trulicity, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 7: Global Glucagon-like Peptide 1 Market, Sub-Segmentation Of Ozempic, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 8: Global Glucagon-like Peptide 1 Market, Sub-Segmentation Of Victoza, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 9: Global Glucagon-like Peptide 1 Market, Sub-Segmentation Of Rybelsus, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 10: Global Glucagon-like Peptide 1 Market, Sub-Segmentation Of Other Types, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 11: Global Glucagon-like Peptide 1 Market, Split By Region, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 12: Global Glucagon-like Peptide 1 Market, Split By Country, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 13: Asia-Pacific, Glucagon-like Peptide 1 Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 14: Asia-Pacific, Glucagon-like Peptide 1 Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 15: Asia-Pacific, Glucagon-like Peptide 1 Market, Segmentation By End-Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 16: China, Glucagon-like Peptide 1 Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 17: China, Glucagon-like Peptide 1 Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 18: China, Glucagon-like Peptide 1 Market, Segmentation By End-Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 19: India, Glucagon-like Peptide 1 Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 20: India, Glucagon-like Peptide 1 Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 21: India, Glucagon-like Peptide 1 Market, Segmentation By End-Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 22: Japan, Glucagon-like Peptide 1 Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 23: Japan, Glucagon-like Peptide 1 Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 24: Japan, Glucagon-like Peptide 1 Market, Segmentation By End-Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 25: Australia, Glucagon-like Peptide 1 Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 26: Australia, Glucagon-like Peptide 1 Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 27: Australia, Glucagon-like Peptide 1 Market, Segmentation By End-Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 28: Indonesia, Glucagon-like Peptide 1 Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 29: Indonesia, Glucagon-like Peptide 1 Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 30: Indonesia, Glucagon-like Peptide 1 Market, Segmentation By End-Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 31: South Korea, Glucagon-like Peptide 1 Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 32: South Korea, Glucagon-like Peptide 1 Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 33: South Korea, Glucagon-like Peptide 1 Market, Segmentation By End-Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 34: Western Europe, Glucagon-like Peptide 1 Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 35: Western Europe, Glucagon-like Peptide 1 Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 36: Western Europe, Glucagon-like Peptide 1 Market, Segmentation By End-Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 37: UK, Glucagon-like Peptide 1 Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 38: UK, Glucagon-like Peptide 1 Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 39: UK, Glucagon-like Peptide 1 Market, Segmentation By End-Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 40: Germany, Glucagon-like Peptide 1 Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 41: Germany, Glucagon-like Peptide 1 Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 42: Germany, Glucagon-like Peptide 1 Market, Segmentation By End-Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 43: France, Glucagon-like Peptide 1 Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 44: France, Glucagon-like Peptide 1 Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 45: France, Glucagon-like Peptide 1 Market, Segmentation By End-Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 46: Italy, Glucagon-like Peptide 1 Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 47: Italy, Glucagon-like Peptide 1 Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 48: Italy, Glucagon-like Peptide 1 Market, Segmentation By End-Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 49: Spain, Glucagon-like Peptide 1 Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 50: Spain, Glucagon-like Peptide 1 Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 51: Spain, Glucagon-like Peptide 1 Market, Segmentation By End-Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 52: Eastern Europe, Glucagon-like Peptide 1 Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 53: Eastern Europe, Glucagon-like Peptide 1 Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 54: Eastern Europe, Glucagon-like Peptide 1 Market, Segmentation By End-Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 55: Russia, Glucagon-like Peptide 1 Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 56: Russia, Glucagon-like Peptide 1 Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 57: Russia, Glucagon-like Peptide 1 Market, Segmentation By End-Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 58: North America, Glucagon-like Peptide 1 Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 59: North America, Glucagon-like Peptide 1 Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 60: North America, Glucagon-like Peptide 1 Market, Segmentation By End-Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 61: USA, Glucagon-like Peptide 1 Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 62: USA, Glucagon-like Peptide 1 Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 63: USA, Glucagon-like Peptide 1 Market, Segmentation By End-Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 64: Canada, Glucagon-like Peptide 1 Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 65: Canada, Glucagon-like Peptide 1 Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 66: Canada, Glucagon-like Peptide 1 Market, Segmentation By End-Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 67: South America, Glucagon-like Peptide 1 Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 68: South America, Glucagon-like Peptide 1 Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 69: South America, Glucagon-like Peptide 1 Market, Segmentation By End-Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 70: Brazil, Glucagon-like Peptide 1 Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 71: Brazil, Glucagon-like Peptide 1 Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 72: Brazil, Glucagon-like Peptide 1 Market, Segmentation By End-Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 73: Middle East, Glucagon-like Peptide 1 Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 74: Middle East, Glucagon-like Peptide 1 Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 75: Middle East, Glucagon-like Peptide 1 Market, Segmentation By End-Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 76: Africa, Glucagon-like Peptide 1 Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 77: Africa, Glucagon-like Peptide 1 Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 78: Africa, Glucagon-like Peptide 1 Market, Segmentation By End-Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 79: Novo Nordisk AS Financial Performance
  • Figure 80: Sanofi SA Financial Performance
  • Figure 81: Eli Lilly and Co Financial Performance
  • Figure 82: AstraZeneca plc Financial Performance
  • Figure 83: Pfizer Inc Financial Performance

Explore the key trends, growth drivers, and market forecast for the global circular polymer market through 2029.

Read More About Explore the key trends, growth drivers, and market forecast for the global circular polymer market through 2029.

Examine TBRC’s analysis of market growth, applications, and regional demand trends for Hypochlorous Acid.

Read More About Examine TBRC’s analysis of market growth, applications, and regional demand trends for Hypochlorous Acid.

How the Cellulase Market is Positioned for Growth: Trends, Market Size, and Future Opportunities (2025-2034)

Read More About How the Cellulase Market is Positioned for Growth: Trends, Market Size, and Future Opportunities (2025-2034)

Top Growth Trends in the Cellulose Derivatives Market: Insights into Market Size and Opportunities for 2025-2034

Read More About Top Growth Trends in the Cellulose Derivatives Market: Insights into Market Size and Opportunities for 2025-2034

Unlocking Opportunities in the Composite Intermediate Bulk Containers Market: Key Trends, Market Growth, and Forecast Insights

Read More About Unlocking Opportunities in the Composite Intermediate Bulk Containers Market: Key Trends, Market Growth, and Forecast Insights

Key Insights into the Coniferyl Alcohol Market: Trends, Growth Rate, and Opportunities Through 2034

Read More About Key Insights into the Coniferyl Alcohol Market: Trends, Growth Rate, and Opportunities Through 2034

Glucagon-like Peptide 1 Global Market Report 2025 – By Product (Trulicity, Ozempic, Victoza, Rybelsus, Other Types), By Route of Administration (Oral, Parenteral, Other Routes), By End-Users (Hospitals, Specialty Clinics...

View Report

Peptide Therapeutics Global Market Report 2025 – By Type (Generic, Branded), By Route of Administration (Parenteral, Mucosal, Oral, Transdermal), By Application (Cancer, Cardiovascular Diseases, Central Nervous Systems, ...

View Report

Peptide Synthesis Global Market Report 2025 – By Product And Service (Reagents, Equipment, Services), By Technology (Solid-Phase Peptide Synthesis, Solution-Phase Peptide Synthesis, Hybrid And Recombinant Technology), By...

View Report

Peptide Based Metabolic Disorders Therapeutics Global Market Report 2025 – By Drug Type (Liraglutide, Exenatide, Other Drug Type), By Application (Lysosomal Storage Diseases, Diabetes, Obesity, Hypercholesterolemia, Othe...

View Report

G-Protein Coupled Receptors Global Market Report 2025 – By Product (Cell Lines, Detection Kits, Cell Culture Reagents, Ligands), By Assay (CAMP Functional Assays, Calcium Functional Assays, ß-Arrestin Functional Assays, ...

View Report

Cell Penetrating Peptide Global Market Report 2025 – By Type (Synthetic Cell Penetrating Peptides, Protein-Derived Cell Penetrating Peptides, Chimeric Cell Penetrating Peptides), By Application (Drug Delivery, Gene Deliv...

View Report

GLP-1 Receptor Agonist Global Market Report 2025 – By Drug Class (Exenatide, Liraglutide, Dulaglutide, Lixisenatide, Other Drugs ), By Route Of Administration (Parenteral, Oral ), By End Users (Hospitals, Surgical Clinic...

View Report

Aminoglycosides Global Market Report 2025 – By Product (Neomycin, Tobramycin, Gentamicin, Amikacin, Paromomycin, Streptomycin, Kanamycin, Other Products), By Route Of Administration (Injectables (Parenteral), Feed, Intra...

View Report

Frequently Asked Questions

Glucagon-like peptide 1 refers to a type of amino acid hormone of peptide that is produced in the L-cells of the intestinal epithelial endocrine. Glucagon-like peptide 1 is used to treat diseases and conditions such as diabetes and obesity respectively. For further insights on this market, request a sample here

The market major growth driver - Escalating Diabetes Prevalence Drives The Global Glucagon-Like Peptide 1 Market. For further insights on this market, request a sample here

The glucagon-like peptide 1 market size has grown strongly in recent years. It will grow from $20.88 billion in 2024 to $22.06 billion in 2025 at a compound annual growth rate (CAGR) of 5.7%. The growth in the historic period can be attributed to rising prevalence of diabetes, focus on improved diabetes management, patient preference for injectable therapies, clinical efficacy and safety profiles, advancements in diabetes research. The glucagon-like peptide 1 market size is expected to see strong growth in the next few years. It will grow to $30.5 billion in 2029 at a compound annual growth rate (CAGR) of 8.4%. The growth in the forecast period can be attributed to emergence of oral glp-1 therapies, focus on personalized medicine, integration in diabetes treatment algorithms, patient-centric approaches in healthcare. Major trends in the forecast period include market expansion in emerging economies, regulatory approvals for new formulations, focus on personalized medicine, patient education and awareness programs, competitive landscape dynamics. For further insights on this market, request a sample here

The glucagon-like peptide 1market covered in this report is segmented –
1) By Product: Trulicity, Ozempic, Victoza, Rybelsus, Other Types
2) By Route of Administration: Oral, Parenteral, Other Routes
3) By End-Users: Hospitals, Specialty Clinics, Other End Users Subsegments:
1) By Trulicity: Injection (pre-filled pen), Dosage forms (0.75 mg, 1.5 mg, etc.)
2) By Ozempic: Injection (pre-filled pen), Dosage forms (0.5 mg, 1 mg, etc.)
3) By Victoza: Injection (pre-filled pen), Dosage forms (1.2 mg, 1.8 mg, etc.)
4) By Rybelsus: Oral tablet (3 mg, 7 mg, 14 mg)
5) By Other Types: Experimental formulations, Combination products with other medications, Alternative delivery systems For further insights on this market, request a sample here

North America was the largest region in the glucagon-like peptide 1 market in 2024. The regions covered in the glucagon-like peptide 1 market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa For further insights on this market, request a sample here.

Major companies operating in the glucagon-like peptide 1 market include Novo Nordisk AS, Sanofi SA, Eli Lilly and Co, AstraZeneca plc, Pfizer Inc, Boehringer Ingelheim International GmbH, F Hoffmann-La Roche Ltd, Bristol-Myers Squibb Company, Baxter, Hikma Pharmaceuticals plc, Zealand Pharma A/S, Intarcia Therapeutics Inc., GlaxoSmithKline plc, Jiangsu Hansoh Pharmaceutical Group Co Ltd, Shanghai Benemae Pharmaceutical Corporation, Adocia, Biocon, Hanmi Pharmaceutical Co Ltd, Ligand Pharmaceuticals Incorporated, Advinus Therapeutics Ltd, Mitsubishi Tanabe Pharma Corporation, Daiichi Sankyo Company Limited, Sun Pharmaceutical Industries Ltd, Union Chimique Belge, Amylin Pharmaceuticals LLC, Academic Pharmaceuticals Inc, ConjuChem Biotechnologies, MannKind Corporation:, Provention Bio Inc, Regeneron Pharmaceuticals . For further insights on this market, request a sample here.

Major trends in this market include Novo Nordisk Introduces Wegovy Therapy For Weight Management. For further insights on this market, request a sample here.

Customer representative image Book your 30 minutes free consultation with our research experts
Contact Us
Global Glucagon-like Peptide 1 Market Report 2025

Wait, we have a special offer for you! ✋

Get your exclusive 20% discount only on the Global Market Reports now using the code ONLINE20*

YES, get the discount! No, I'd pay the full price

*Copy paste the discount code in the cart

Back to top WhatsApp icon